Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.
Locatelli F, Valsecchi MG, Möricke A, Zimmermann M, Gruhn B, Biondi A, Kulozik AE, Silvestri D, Bodmer N, Putti MC, Burdach S, Micalizzi C, Teigler-Schlegel A, Ritter J, Pession A, Cario G, Bielack S, Basso G, Klingebiel T, Vinti L, Rizzari C, Attarbaschi A, Santoro N, Parasole R, Mann G, Karawajew L, Haas OA, Conter V, Schrappe M. Locatelli F, et al. Among authors: bodmer n. Blood. 2017 Nov 9;130(19):2146-2149. doi: 10.1182/blood-2017-05-782086. Epub 2017 Sep 22. Blood. 2017. PMID: 28939722 Free article. Clinical Trial. No abstract available.
Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials.
Raetz EA, Rebora P, Conter V, Schrappe M, Devidas M, Escherich G, Imai C, De Moerloose B, Schmiegelow K, Burns MA, Elitzur S, Pieters R, Attarbaschi A, Yeoh A, Pui CH, Stary J, Cario G, Bodmer N, Moorman AV, Buldini B, Vora A, Valsecchi MG. Raetz EA, et al. Among authors: bodmer n. J Clin Oncol. 2023 Nov 10;41(32):5025-5034. doi: 10.1200/JCO.23.00088. Epub 2023 Jul 24. J Clin Oncol. 2023. PMID: 37487146
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols.
Cario G, Leoni V, Conter V, Attarbaschi A, Zaliova M, Sramkova L, Cazzaniga G, Fazio G, Sutton R, Elitzur S, Izraeli S, Lauten M, Locatelli F, Basso G, Buldini B, Bergmann AK, Lentes J, Steinemann D, Göhring G, Schlegelberger B, Haas OA, Schewe D, Buchmann S, Moericke A, White D, Revesz T, Stanulla M, Mann G, Bodmer N, Arad-Cohen N, Zuna J, Valsecchi MG, Zimmermann M, Schrappe M, Biondi A. Cario G, et al. Among authors: bodmer n. Haematologica. 2020 Jul;105(7):1887-1894. doi: 10.3324/haematol.2019.231720. Epub 2019 Oct 10. Haematologica. 2020. PMID: 31601692 Free PMC article.
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective cohort study.
Ghorashian S, Jacoby E, De Moerloose B, Rives S, Bonney D, Shenton G, Bader P, Bodmer N, Quintana AM, Herrero B, Algeri M, Locatelli F, Vettenranta K, Gonzalez B, Attarbaschi A, Harris S, Bourquin JP, Baruchel A. Ghorashian S, et al. Among authors: bodmer n. Lancet Haematol. 2022 Oct;9(10):e766-e775. doi: 10.1016/S2352-3026(22)00225-3. Epub 2022 Sep 6. Lancet Haematol. 2022. PMID: 36084658 Free article.
65 results